Lantern Pharma Inc. (LTRN)

Market Cap	37.53M
Revenue (ttm)	n/a
Net Income (ttm)	-20.78M
Shares Out	10.78M
EPS (ttm)	-1.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,117
Open	3.490
Previous Close	3.490
Day's Range	3.365 - 3.490
52-Week Range	2.550 - 7.210
Beta	1.63
Analysts	Buy
Price Target	25.00 (+618.39%)
Earnings Date	May 8, 2025

About LTRN

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2020
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: LTRN
• Website: https://www.lanternpharma.com

Analyst Forecast

According to 2 analysts, the average rating for LTRN stock is "Buy." The 12-month stock price forecast is $25.0, which is an increase of 618.39% from the latest price.

Price Target

$25.0

(618.39% upside)

Analyst Consensus: Buy